Recursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock

Key Takeaways RXRX stock rose 5.5% in a month after acquiring Rallybio's stake in their joint HPP drug venture. The deal gives RXRX full control of REV102, a potential oral treatment for hypophosphatasia. RXRX also retains a robust pipeline, $509M in cash, and ongoing partnerships with major pharma players.Recursion Pharmaceuticals (RXRX) shares have gained 5.5% in a month. The stock gained momentum after the company announced the acquisition of Rallybio’s full stake in their joint venture earlier this mo ...